Novartis Pharmaceutical Corporation, San Carlos, CA, USA
Andrei Blasko, Ph.D., FRSC, is a Senior Fellow at Novartis Pharmaceuticals Corp. working in Inhalation Technical Development. Previously Dr. Blasko was Director of Analytical Method Development and co-lead a Drug Discovery & CMC Development program at Pain Therapeutics, Inc., where he managed projects in drug discovery, structural biology, and analytical method development up to NDA submission. Other companies he worked with include Celera (inflammation/oncology), Pfizer/Pharmacia/Sugen (oncology) and Roche Bioscience (neurobiology), after finishing postdoctoral work at the University of California Santa Barbara. Dr. Blasko has 28 years of experience in physical-organic and bioorganic chemistry with diverse background in drug discovery and CMC development, screening, lead optimization, and clinical candidate selection with expertise in analytical, preformulation, formulation, and chemical development. Dr. Blasko is a Fellow of the Royal Society of Chemistry (FRSC) and a member of the American Chemical Society (ACS), American Association of Pharmaceutical Scientists (AAPS), and International Pharmaceutical Federation (FIP).
Chemical biology, analytical, preformulation, formulation, drug discovery and drug development for CNS.